The effect of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human volunteers

J Wolf; L Friberg; J Jensen; P B Hansen; A R Andersen; N A Lassen

The effect of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human volunteers

J Wolf, L Friberg, J Jensen, P B Hansen, A R Andersen, N A Lassen

Klinisk Fysiologisk/Nuklearmedicinsk Afd.

7 Citationer (Scopus)

Abstrakt

The influence of the benzodiazepine antagonist flumazenil on regional cerebral blood flow (rCBF) was investigated in ten healthy, alert volunteers. The design was a randomized, placebo-controlled, double-blind, cross-over study. rCBF was measured by 133-Xe inhalation and single photon emission computerized tomography, SPECT, immediately before, and 5 and 35 min after intravenous injection of flumazenil 1.0 mg or placebo. In addition, mean arterial blood pressures or PaCO2, rCBF were analysed for changes in various regions of interest (RoI). No alterations were found either in the global CBF or in rCBF in RoI after flumazenil injection. The results showed that a clinically active dose of flumazenil did not directly affect the cerebral circulation in the normal brain and indicated absence of significant intrinsic activity of the drug.

Originalsprog	Engelsk
Tidsskrift	Acta Anaesthesiologica Scandinavica
Vol/bind	34
Udgave nummer	8
Sider (fra-til)	628-31
Antal sider	4
ISSN	0001-5172
Status	Udgivet - nov. 1990

Citationsformater

@article{71fbf63b629b4537a4f90b992fb62a67,

title = "The effect of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human volunteers",

abstract = "The influence of the benzodiazepine antagonist flumazenil on regional cerebral blood flow (rCBF) was investigated in ten healthy, alert volunteers. The design was a randomized, placebo-controlled, double-blind, cross-over study. rCBF was measured by 133-Xe inhalation and single photon emission computerized tomography, SPECT, immediately before, and 5 and 35 min after intravenous injection of flumazenil 1.0 mg or placebo. In addition, mean arterial blood pressures or PaCO2, rCBF were analysed for changes in various regions of interest (RoI). No alterations were found either in the global CBF or in rCBF in RoI after flumazenil injection. The results showed that a clinically active dose of flumazenil did not directly affect the cerebral circulation in the normal brain and indicated absence of significant intrinsic activity of the drug.",

keywords = "Adult, Blood Pressure, Brain, Carbon Dioxide, Cerebrovascular Circulation, Double-Blind Method, Female, Flumazenil, Humans, Injections, Intravenous, Male, Placebos, Tomography, Emission-Computed, Single-Photon, Xenon Radioisotopes",

author = "J Wolf and L Friberg and J Jensen and Hansen, {P B} and Andersen, {A R} and Lassen, {N A}",

year = "1990",

month = nov,

language = "English",

volume = "34",

pages = "628--31",

journal = "Acta Anaesthesiologica Scandinavica",

issn = "0001-5172",

publisher = "Wiley-Blackwell Munksgaard",

number = "8",

}

TY - JOUR

T1 - The effect of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human volunteers

AU - Wolf, J

AU - Friberg, L

AU - Jensen, J

AU - Hansen, P B

AU - Andersen, A R

AU - Lassen, N A

PY - 1990/11

Y1 - 1990/11

N2 - The influence of the benzodiazepine antagonist flumazenil on regional cerebral blood flow (rCBF) was investigated in ten healthy, alert volunteers. The design was a randomized, placebo-controlled, double-blind, cross-over study. rCBF was measured by 133-Xe inhalation and single photon emission computerized tomography, SPECT, immediately before, and 5 and 35 min after intravenous injection of flumazenil 1.0 mg or placebo. In addition, mean arterial blood pressures or PaCO2, rCBF were analysed for changes in various regions of interest (RoI). No alterations were found either in the global CBF or in rCBF in RoI after flumazenil injection. The results showed that a clinically active dose of flumazenil did not directly affect the cerebral circulation in the normal brain and indicated absence of significant intrinsic activity of the drug.

AB - The influence of the benzodiazepine antagonist flumazenil on regional cerebral blood flow (rCBF) was investigated in ten healthy, alert volunteers. The design was a randomized, placebo-controlled, double-blind, cross-over study. rCBF was measured by 133-Xe inhalation and single photon emission computerized tomography, SPECT, immediately before, and 5 and 35 min after intravenous injection of flumazenil 1.0 mg or placebo. In addition, mean arterial blood pressures or PaCO2, rCBF were analysed for changes in various regions of interest (RoI). No alterations were found either in the global CBF or in rCBF in RoI after flumazenil injection. The results showed that a clinically active dose of flumazenil did not directly affect the cerebral circulation in the normal brain and indicated absence of significant intrinsic activity of the drug.

KW - Adult

KW - Blood Pressure

KW - Brain

KW - Carbon Dioxide

KW - Cerebrovascular Circulation

KW - Double-Blind Method

KW - Female

KW - Flumazenil

KW - Humans

KW - Injections, Intravenous

KW - Male

KW - Placebos

KW - Tomography, Emission-Computed, Single-Photon

KW - Xenon Radioisotopes

M3 - Journal article

C2 - 2125793

VL - 34

SP - 628

EP - 631

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 8

ER -

The effect of the benzodiazepine antagonist flumazenil on regional cerebral blood flow in human volunteers

Abstrakt

Fingeraftryk

Citationsformater